Spero Therapeutics is a global, multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. Our mission as a leader in the field of Gram-negative antibiotics is to combat MDR infections by developing highly differentiated and transformative antibiotics through cutting edge science that address critical unmet needs.
Spero Therapeutics is highly committed to advancing novel treatment approaches for bacterial infections. Our world-class team of biotechnology and biopharmaceutical experts embrace the Italian word “spero” which means “hope.” It is our ultimate goal to bring hope to patients and families of loved ones suffering from serious infections.
As we strive to combat the high unmet medical need associated with drug-resistant bacterial infections, our most advanced product candidate, tebipenem HBr, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat multi-drug resistant (MDR) Gram-negative infections. In September 2020, we announced positive Phase 3 data for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI). If approved by the FDA, tebipenem HBr would be the first oral cUTI drug to earn approval in 26 years, which would be an important achievement given the high levels of resistance to currently available oral therapies. Treatment with effective orally administered antibiotics may help avoid hospitalization and in hospital setting it may help accelerate hospital discharge by delivering a more convenient and cost-effective treatment for patients.
We are also developing SPR720, an oral antibacterial agent currently under investigation for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease.
We are also developing SPR206, an IV-administered next generation polymyxin product candidate developed from our potentiator platform, as an innovative potential option to treat MDR Gram-negative bacterial infections.
Founded in 2013, and named as one Boston’s Best Places to Work in 2020 and 2017 by the Boston Business Journal, Spero Therapeutics is also the recipient of the first-ever 2017 Xconomy Startup of the Year Award. We believe that our novel product candidates, if approved, will have meaningful impact on patient health and significant commercial applications for the treatment of MDR infections in both the hospital and community settings.
Novel carbapenem antibiotic that completed a Phase 3 pivotal trial in complicated urinary tract infection. Oral tebipenem HBr demonstrated noninferiority to intravenous ertapenem in cUTI and AP with a comparable safety and tolerability profile.
Novel agent with the potential to be the first oral antibiotic approved for the treatment of NTM disease.
Spero Therapeutics has assembled a highly experienced and uniquely qualified team of biotechnology and biopharmaceutical experts led by President and CEO, Ankit Mahadevia, MD. Openly transparent and highly respectful, our leadership team firmly believes that Spero Therapeutics’ employees are their most important and valued resource.